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ABSTRACT
CONTEXT AND OBJECTIVE: The lack of availability of antidotes in emergency services is a worldwide con-
cern. The aim of the present study was to evaluate the availability of antidotes used for treating poisoning 
in Campinas (SP). 
DESIGN AND SETTING: This was a cross-sectional study of emergency services in Campinas, conducted 
in 2010-2012.
METHODS: The availability, amount in stock, place of storage and access time for 26 antidotal treatments 
was investigated. In the hospitals, the availability of at least one complete treatment for a 70 kg adult over 
the first 24 hours of admission was evaluated based on stock and access recommendations contained in 
two international guidelines.
RESULTS: 14 out of 17 functioning emergency services participated in the study, comprising pre-hospital 
services such as the public emergency ambulance service (SAMU; n = 1) and public emergency rooms for 
admissions lasting ≤ 24 hours (UPAs; n = 3), and 10 hospitals with emergency services. Six antidotes (atro-
pine, sodium bicarbonate, diazepam, phytomenadione, flumazenil and calcium gluconate) were stocked 
in all the services, followed by 13 units that also stocked activated charcoal, naloxone and diphenhydr-
amine or biperiden. No service stocked all of the recommended antidotes; only the regional Poison Con-
trol Center had stocks close to recommended (22/26 antidotal treatments). The 10 hospitals had almost 
half of the antidotes for starting treatments, but only one quarter of the antidotes was present with stocks 
sufficient for providing treatment for 24 hours. 
CONCLUSION: The stock of antidotes for attending poisoning emergencies in the municipality of Campi-
nas is incomplete and needs to be improved. 
RESUMO
CONTEXTO E OBJETIVO: A carência de disponibilidade de antídotos nas salas de emergência é uma preo-
cupação mundial. O objetivo foi avaliar a disponibilidade de antídotos usados no tratamento de pacientes 
intoxicados no município de Campinas (SP).
TIPO DE ESTUDO E LOCAL: Trata-se de estudo transversal de serviços de emergência de Campinas, rea-
lizado de 2010-2012.
MÉTODOS: A disponibilidade, quantidade estocada, local de armazenamento e tempo de acesso a 26 
tratamentos antidotais foi investigada. Nos hospitais, foi avaliada também a disponibilidade de pelo me-
nos um tratamento completo para um adulto de 70 kg nas primeiras 24 horas da admissão, com base em 
recomendações de estoques e acesso contidas em duas diretrizes internacionais.
RESULTADOS: 14 dentre 17 serviços de emergência em funcionamento participaram do estudo, que 
incluiu serviços pré-hospitalares, como o Serviço de Atendimento Móvel de Urgência (SAMU, n = 1) e 
três Unidades de Pronto Atendimento (UPAs, internação limitada até 24 horas), além de 10 hospitais com 
emergência. Seis antídotos (atropina, bicarbonato de sódio, diazepam, fitomenadiona, flumazenil e gluco-
nato de cálcio) estavam estocados em todos os serviços, seguidos de 13 que também estocavam carvão 
ativado, naloxona, difenidramina ou biperideno. Nenhum serviço tinha estoque de todos os antídotos 
recomendados; somente o Centro de Controle de Intoxicações regional tinha estoque próximo ao perfil 
recomendado (22/26 opções terapêuticas). Os 10 hospitais tinham quase metade dos antídotos necessá-
rios para iniciar tratamento, mas somente um quarto dos antídotos estava em estoques suficientes para 
oferecer tratamento por 24 horas.
CONCLUSÃO: O estoque de antídotos para atendimento de emergências toxicológicas no município de 
Campinas é incompleto e deve ser melhorado.
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INTRODUCTION
The lack of adequate and readily available antidotes in emergency 
services is a worldwide concern.1-9 Various factors have been corre-
lated with antidote unavailability, including product shelf-life, the 
high cost of certain antidotes, the classification of some antidotes 
as orphan drugs (i.e. drugs of low commercial interest that qualify 
for incentives such as tax relief, depending on each country’s pol-
icy) and difficulty in importing antidotes from certain countries.8
Guidelines may help to organize antidote stocks in emergency 
services in acute hospitals.1-4,9,10 The United Kingdom (UK) guide-
lines, which were initially published in 2008 and are regularly revised 
and updated, stipulate that antidote stocks should be sufficient for 
the initial treatment of a 70 kg adult patient and for treatment dur-
ing the first 24 hours. In these guidelines, antidote stocks are also 
classified according to availability, i.e. antidotes held in emergency 
departments for immediate use, antidotes held in hospital pharma-
cies or dispensaries for use in emergency departments within one 
hour of patient admission, and antidotes that are rarely used or for 
which the time interval until use in emergency departments is not 
critical, with stocks held in a supraregional center.3,10
The United States (US) guidelines also classified antidotes based 
on their optimal access time.4 This list of antidotes and their mini-
mum stocks was defined based on a systematic review of the litera-
ture followed by evaluation by a panel of experts, who assessed the 
efficacy, safety, influence of access time on subsequent treatment 
and dose required to treat a 100 kg-individual.4 Based on antidote 
guidelines, verification of antidote stocks in Canada had a beneficial 
impact on antidote availability in acute hospitals.1,2 In that context, 
two audits were held: one year before and one after the publication 
of antidote stockpile guidelines. In the second audit, conformity 
was found to have significantly increased, reaching at least 62% 
of the recommended stock for each antidote. To date, assessments 
of antidote availability in the Brazilian context are still lacking.
OBJECTIVE
In this study, we assessed the availability of antidotes used to 
treat poisoning at the emergency services of the municipality of 
Campinas, in the state of São Paulo, southeastern Brazil. The anal-
ysis included both pre-hospital services and acute care hospitals.
METHODS
Study design and setting
This investigation was a cross-sectional study conducted among 
emergency services in Campinas, São Paulo, from April 2010 to 
April 2012. Campinas had an estimated population of 1.15 mil-
lion inhabitants in 2014.11 
We identified 17 emergency services registered in the National 
Registry of Healthcare Establishments of the Department of 
Information of the Brazilian National Health System (Sistema 
Único de Saúde, SUS): 10 private and seven public.12 We attempted 
to include the universe of eligible participants, and thus no sample 
size was predetermined.
Participants
All emergency services in the municipality were eligible for this 
study: public pre-hospital services (the emergency ambulance 
service [Serviço de Atendimento Móvel de Urgência, SAMU] 
and emergency rooms with limited capacity for admission, i.e. 
admission for up to 24 hours [Unidade de Pronto Atendimento, 
UPA]); and any hospital that had inpatient beds and could be 
required to treat a poisoned patient (emergency hospitals, also 
referred to as acute hospitals). 
Variables
The primary endpoint was the frequency of antidotal treatment 
availability in the emergency service that was surveyed (pre-hos-
pital or hospital). The secondary endpoints were the adequacy of 
the stockpile for the initial and subsequent 24 hours of treatment 
for an adult of 70 kg in the emergency departments. 
We considered “antidote” to be one or more medicine that is 
appropriate for treating a case of poisoning. As a result, the list has 
more medicines than antidotes. 
The variables of the institutions were their nature (public/private), 
complexity, number of beds and educational attainment of the phar-
macy director. With regard to the antidotes, the variables were the 
availability of each medicine, amounts available in the main storage 
and in the emergency room, and time taken to make the medicine 
available in the emergency room (< 1 hour or ≥ 1 hour). 
Data sources and measurement
The list of recommended antidotes was based on the UK (2008) 
and US (2009) guidelines (Table 1).3,4 We excluded the antidotes 
recommended for stocking in supraregional centers, since these 
do not need to be available in all emergency rooms. We  also 
excluded phentolamine, which was recommended in only one 
guideline; and potassium iodide, because of lack of clinical 
demand within the Brazilian context. 
The antidote doses and quantities recommended for the ini-
tial treatment of a 70 kg adult patient over the first 24 hours after 
exposure were obtained from the UK guidelines and from stan-
dard texts of clinical toxicology.3,13 These were then adapted for the 
pharmaceutical preparations available on the Brazilian market, as 
shown in Table 1. This led to 26 antidote options, corresponding 
to 30 different medicines. For comprehensiveness, from this point 
onwards, we will call these antidote options simply the “antidotes”. 
The availability on the Brazilian market was defined from a pre-
vious study and from the authors’ expertise in this field.8 In cases 
Antidote availability in the municipality of Campinas, São Paulo, Brazil | ORIGINAL ARTICLE
Sao Paulo Med J. 2017; 135(1):15-22     17
in which the antidote was not commercially available, we consid-
ered the possibility of extemporaneous preparation or importation.
We elaborated a semi-structured questionnaire in order to 
gather data on the institutions and antidotes. The person respon-
sible for the pharmacy of the emergency service answered the 
questionnaire, which was provided on paper.
We did not assess antivenin stockpiles for treating bites/stings 
caused by native venomous animals. The National Program for 
Control of Venomous Animals, of the Brazilian Ministry of Health, 
supplies the stockpiles of antivenin based on the notifications of 
cases. In Campinas, antivenin stockpiles are available from the 
regional Poison Control Center.14
Control of bias
To avoid selection bias, we invited all the eligible emergency ser-
vices to participate, by means of a written invitation and further 
follow-up calls. We gave assurances of confidentiality by stat-
ing that the analysis would be performed in an aggregated man-
ner and that no healthcare service would be negatively exposed 
through identification in the study.
Two experienced clinical toxicologists (FB, EMDC) reviewed 
the questionnaire. In this step, the physicians assessed its com-
prehensiveness and compatibility with Brazilian clinical settings. 
Although the list of antidotes was based on international guidelines 
(because of the lack of national standardization), it was adapted to 
Item Antidote, route Pharmaceutical preparation Recommended stockpile Clinical indication*
1
Acetylcysteine, IV 100 mg/ml; 3 ml ampoule 70 ampoules
Paracetamol
Acetylcysteine, PO 600 mg sachet 155 sachets
2 Activated charcoal, PO 10 g, 25 g or 50 g sachets 300 g (e.g., 6 x 50 g sachets)
Adsorbent for gastrointestinal 
decontamination
3 Anti-digoxin antibodies, IV 38 mg vial 10 vials Cardioactive steroids 
4 Atropine, IV 250 µg/ml; 1 ml ampoule 300 ampoules Cholinesterase inhibitors
5 Calcium folinate, IV
300 mg vial; 50 mg vial; 3 mg/ml;  
1 ml ampoule
3 x 300 mg vials, or 16 x 50 mg 
vials, or 240 ampoules
Methotrexate; methanol, formic acid
6 Calcium gluconate, IV 10% (100 mg/ml); 10 ml ampoules 12 ampoules
Calcium channel blockers, 
hydrofluoric acid
7 Calcium gluconate, topic gel 2.5%; 25 g pack 1 pack Hydrofluoric acid burns
8 Dantrolene, IV 20 mg vial 35 vials Neuroleptic malignant syndrome
9 Desferrioxamine, IV 500 mg vial 12 vials Iron salts
10 Diazepam, IV 5 mg/ml; 2 ml ampoule 4 ampoules
Convulsions, agitation and 
precordial pain
11 Dimercaprol, IM 100 mg/ml; 1 ml ampoule 15 ampoules Mercury, arsenic, gold
12
Diphenhydramine, IV 50 mg/ml; 1 ml ampoule 4 ampoules
Dystonic reactions
Biperiden, IV 5 mg/ml; 1 ml ampoule 4 ampoules
13 Flumazenil, IV 100 µg/ml; 5 ml ampoule 4 ampoules Benzodiazepines
14
Fomepizole, IV 5 mg/ml; 20 ml ampoule 25 ampoules
Methanol, ethylene glycol
Ethanol, IV 100%; 10 ml ampoule 30 ampoules
15 Glucagon, IV 1 mg vial 50 vials
Beta blockers, calcium channel 
blockers, tricyclic antidepressants
16
Hydroxocobalamin, IV 5 g pack 2 packs
CyanideSodium nitrite, IV and 3% (30 mg/ml); 10 ml ampoule 1 ampoule
sodium thiosulfate, IV 25% (250 mg/ml); 10 ml ampoule 8 ampoules
17 Methylene blue, IV 1-2 mg/ml; 5 ml ampoule 3-6 ampoules Methemoglobin-inducing agents
18 Naloxone, IV 0.4 mg/ml; 1 ml ampoule 25 ampoules Opioids
19 Octreotide, IV 0.1 mg/ml; 1 ml ampoule 2 ampoules Oral hypoglycemic agents
20 Physostigmine, IV 1 mg/ml; 2 ml ampoule 2 ampoules Anticholinergic agents
21 Phytomenadione (vitamin K), IV 10 mg/ml; 1 ml ampoule 1 ampoule Coumarin anticoagulants
22 Polyethylene glycol 3350, PO Sachets, reconstituted with water (2 l) 12 sachets
Iron salts, lithium, packs of cocaine 
or heroin (body packers)
23 Pralidoxime, IV 1 g vial 5 vials Organophosphates insecticides
24 Protamine sulfate, IV 10 mg/ml; 5 ml ampoule 1 ampoule Heparin
25 Pyridoxine, IV 100 mg/ml; 10 ml ampoule 5 ampoules Isoniazid
26 Sodium bicarbonate, IV 8.4%; 250 ml vial 750 ml (3 vials or 75 ampoules)
Tricyclic antidepressants, serum 
and urinary alkalization 
Table 1. Pharmaceutical preparations and recommended stock for the antidotes evaluated in this study based on sufficient amounts for 
the initial and subsequent 24 hours of treatment of a 70 kg adult patient in the emergency room
*In cases of treatment for a specific type of poisoning, only the name of the agent is shown.
IV = intravenous; IM  = intramuscular; PO = per oral.
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the Brazilian context through the empirical knowledge of these cli-
nicians. Five other healthcare professionals (three physicians and 
two pharmacists) tested and approved the questionnaire in order 
to assure understanding (SLSM, ILG, RJV, MY, SMM). The phar-
macy director of each service filled out the questionnaire to ensure 
correctness. These measures were aimed at limiting potential mea-
surement bias.
In cases involving incomplete questionnaire that was returned, 
we assumed that the antidote in question was not available.
Statistical methods
The data were entered into an Excel (Microsoft Office 2010) 
spreadsheet and were analyzed using simple descriptive statistics. 
We did not perform statistical testing or produce adjusted analy-
ses because of the small sample size.
Ethical aspects
This study was approved by the institutional Research Ethics 
Committee of the School of Medical Sciences, State University of 
Campinas (protocol no. CEP 121/2010). All participants signed a 
free and informed consent statement.
RESULTS
Out of the 17 emergency services that were running at the time 
of the study, 14 (7 public and 7 private) agreed to participate in 
the study. These emergency services were classified either as pre-
hospital (SAMU, n = 1; and UPA, n = 3, 8-21 beds) or as acute 
hospitals (total of 10, of which: < 50 beds, n = 1; 50-250 beds, n = 
8; and > 250 beds, n = 1). The three services not included in this 
survey were all private: one large and two small hospitals. The 
reasons for exclusion were refusal (one large hospital); no person 
responsible for the pharmacy at the time of data collection (one 
small hospital); and no response and subsequent hospital closure 
(one small hospital).
Table 2 shows the list of available antidotes according to the 
emergency service characteristics. All the emergency services 
stocked 6 out of the 26 recommended antidotes: atropine, sodium 
bicarbonate, diazepam, phytomenadione, flumazenil and calcium 
gluconate. Thirteen emergency services also stocked activated char-
coal, naloxone and diphenhydramine or biperiden (thus totaling 
9/26). None of the emergency departments stocked all of the anti-
dotes surveyed and none had anti-digoxin antibodies, fomepizole, 
hydroxocobalamin, physostigmine or pralidoxime. 
Antidotes*
Pre-hospital services Emergency hospitals
Total
n = 14
SAMU UPA Small Medium Large
(ambulance) (8-21 beds) (< 50 beds) (50-250 beds) (> 250 beds) 
n = 1 n = 3 n = 1 n = 8 n = 1
Atropine 1 3 1 8 1 14
Calcium gluconate 10% 1 3 1 8 1 14
Diazepam 1 3 1 8 1 14
Flumazenil 1 3 1 8 1 14
Phytomenadione (vitamin K) 1 3 1 8 1 14
Sodium bicarbonate 1 3 1 8 1 14
Activated charcoal 0 3 1 8 1 13
Diphenhydramine or biperiden 1 2 1 8 1 13
Naloxone 1 2 1 8 1 13
Acetylcysteine 0 0 1 8 1 10
Dantrolene 0 0 1 8 1 10
Methylene blue 0 0 1 8 1 10
Octreotide 0 0 0 7 1 8
Protamine sulfate 0 0 1 5 1 7
Calcium folinate 0 0 0 3 1 4
Ethanol† 0 0 0 3 1 4
Polyethylene glycol 3350 0 0 0 3 1 4
Calcium gluconate gel 0 0 0 0 1 1
Desferrioxamine 0 0 0 0 1 1
Dimercaprol 0 0 0 0 1 1
Pyridoxine 0 0 0 0 1 1
Sodium nitrite and sodium thiosulfate‡ 0 0 0 0 1 1
Glucagon 0 0 0 1 0 1
*No emergency service had anti-digoxin antibodies, physostigmine or pralidoxime; †fomepizole was not available; ‡hydroxocobalamin was not available.
SAMU = Serviço de Atendimento Móvel de Urgência (public emergency ambulance service); UPA = Unidade de Pronto Atendimento (public emergency rooms 
with a limited capacity for admission, usually less than 24 hours).
Table 2. List of antidotes available in Campinas according to the emergency service profiles
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Only the hospital at which the regional Poison Control Center 
is run had antidote stocks close to the recommendation (exclud-
ing the five antidotes mentioned earlier and also glucagon); at this 
service, 100% ethanol was provided instead of fomepizole and 
sodium nitrite/sodium thiosulfate instead of hydroxocobalamin. 
All the emergency hospitals had 12 antidotes with which they 
were able to start treatment within one hour of admission (diaz-
epam, phytomenadione, flumazenil, calcium gluconate, diphen-
hydramine or biperiden, sodium bicarbonate, methylene blue ace-
tylcysteine, atropine, activated charcoal, naloxone and dantrolene) 
(Table 3). To continue the treatment for the first 24 hours in the 
hospitals, the stockpile was adequate for seven antidotes (diaz-
epam, phytomenadione, flumazenil, calcium gluconate, diphen-
hydramine or biperiden, sodium bicarbonate and methylene blue).
DISCUSSION
The pre-hospital and hospital emergency services of Campinas have 
one quarter of the recommended antidotes available for treating 
poisoning. In the hospital setting, all the emergency departments 
stocked almost half of the antidotes for starting treatment, but with 
regard to continuing it for 24 hours, the stockpiles were insuffi-
cient for 75% of the antidotes. Only the reference service, which is 
located in the largest hospital in the city, had an antidote stock that 
approached the recommended stock profile. This situation is simi-
lar to that described in the literature, in which larger hospitals gen-
erally have larger, more diversified antidote stocks.2,5,6
Since no Brazilian recommendations for antidote supply are 
available, the diagnosis provided by the present study was based 
on international guidelines. Although the US and UK guidelines 
for antidote stockpiles can provide a useful starting point, the rec-
ommendations may not be realistic from a clinical or economic 
perspective within our context. 
To better address this issue, we compiled a list of the most prev-
alent poisonings handled by the Campinas Poison Control Center 
in 2014 (Table 4). Our findings suggest that even the pre-hospital 
Table 3. Antidotes available at ten emergency departments 
(emergency hospitals) in the municipality of Campinas, based 
on the time required for accessing them and the adequacy of 
the stock for the initial and subsequent 24 hours of treatment 
for a 70 kg adult patient
*Fomepizole was not available; †hydroxocobalamin was not available. 
ED = emergency department.
Antidotes





Phytomenadione (vitamin K) 10 10
Flumazenil 10 10
Calcium gluconate 10% 10 10
Diphenhydramine or biperiden 10 10
Sodium bicarbonate 10 10
Methylene blue 10 10
Acetylcysteine 10 8
Atropine 10 6




Protamine sulfate 7 7
Calcium folinate 4 4
Polyethylene glycol 3350 4 2
Ethanol* 4 2
Pyridoxine 1 1
Calcium gluconate gel 1 1
Desferrioxamine 1 1
Dimercaprol 1 1
Sodium nitrite and sodium thiosulfate† 1 1
Glucagon 1 0







Selective serotonin uptake inhibitors 220 4.1




Analgesics and antipyretics 242 4.5
Paracetamol 120 2.2
Dipyrone 96 1.8
Histamine H1-receptor antagonists 183 3.4
Venomous animal bites/stings
Scorpion stings 398 7.4
Snake bites 68 1.3






Rodenticides (anticoagulants) 150 2.8
Pyrethroids 122 2.3





Table 4. Most frequent toxic exposures among 5,362 patients followed 
up by the Campinas Poison Control Center in 2014
*Exposures could be for one or more agents; †“Chumbinho” = illegal rodenticide 
used in Brazil since the 1990s containing cholinesterase inhibitors, mainly 
carbamates such as aldicarb.
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services have sufficient amounts of antidotes to provide the initial 
medical treatment in most situations. The epidemiological pat-
tern of poison exposure usually has low variation in terms of the 
agents,15 which was the reason why we chose to present this epi-
demiological data with further updating. 
The following additional limitations of the present survey 
relating to the source of the data should be noted. The information 
on local stocks was supplied solely by the pharmacist responsible 
for the emergency services, with no crosschecking of the data to 
assess reliability. Some fields in the questionnaire were left blank, 
which was conservatively considered to represent stock unavail-
able. Not all of the emergency services in Campinas participated in 
the study, even though the response rate was above 80%. The study 
scope was essentially regional, but it represents the first report of 
antidote availability in emergency services in Brazil.
Making an antidote available does not in itself ensure safety 
and effectiveness in treating cases of poisoning. Flumazenil, which 
was found in all stocks, requires judicious evaluation before use 
for treating benzodiazepine poisoning, since it is contraindicated 
for concomitant treatment with central nervous system depressors 
such as tricyclic antidepressants and carbamazepine.7,16 Single-dose 
activated charcoal can be considered for use in cases involving 
potentially toxic doses of substances that are adsorbed by activated 
charcoal; however, there is no evidence that activated charcoal 
improves the prognosis for patients affected by these substances.17 
Timely administration is another restriction on the effectiveness 
of activated charcoal, which should be done within 60 minutes of 
poison ingestion. Multiple-dose activated charcoal might prevent 
absorption of some drugs that persist in the gastrointestinal tract 
(e.g. modified-release preparations), or increase elimination in 
the postabsorptive phases (enterohepatic or enteroenteric recir-
culation), and should be considered in cases of ingestion of high 
doses of carbamazepine, phenobarbital, dapsone, theophylline or 
quinine, all of which may be life-threatening.18 
Although dantrolene was stocked by the ten acute hospitals 
with surgical centers, as recommended by the Brazilian Society of 
Anesthesiology,19 in most cases the stocks held were insufficient. 
During the data collection period, none of the emergency 
departments had any of the first-option antidotes: anti-digoxin 
antibodies, hydroxocobalamin or fomepizole.7,13 However, some 
less expensive antidotes may be used as alternatives. For exam-
ple, sodium nitrite and sodium thiosulfate (methemoglobiniz-
ing agents and activators of the rhodanese system), instead of 
hydroxocobalamin, are also effective for treating cyanide poi-
soning. However, use of methemoglobinizing agents can be del-
eterious in poisonings resulting from inhalation of toxic gases 
containing high concentrations of carbon monoxide and cyanide, 
especially in urban fires.7,13 In such situations, the first-option 
emergency antidote is hydroxocobalamin.7,13 
Ethanol is an effective alternative to fomepizole for treating 
methanol/ethylene glycol poisoning. On the other hand, despite 
the high cost of fomepizole, it is much simpler to use than etha-
nol.7,13 Fomepizole is particularly useful for treating methanol 
poisoning caused by massive consumption of adulterated spirits.20 
Indeed, fomepizole was included in the list of essential antidotes 
published by the World Health Organization.21
Pyridoxine (a first-choice antidote for treating isoniazid poi-
soning) and dimercaprol (a first-choice antidote for treating acute 
arsenic poisoning) were stocked in the regional reference service. 
Since Brazil is among the countries with high incidence and preva-
lence of tuberculosis,22 access to isoniazid is widespread and this 
increases the risk of toxic exposure. Poisoning due to isoniazid is 
uncommon, but may result in seizures that are very difficult to 
control and that improve with high doses of pyridoxine.13 Acute 
poisoning with arsenic is rare nowadays and cases that do occur 
are generally intentional (attempted suicide and homicide), with 
serious fulminant complications, hence justifying maintenance of 
stocks of dimercaprol in the regional reference service.4,23
Although not investigated in this study, other antidotes should 
be considered for antidote stocks. These antidotes include lipid 
emulsions for dealing principally with systemic poisoning by local 
anesthetics;7,24 cyproheptadine for treating serotoninergic syn-
drome;25 continuous infusion of high doses of insulin and glucose 
as inotropic medicines to counteract poisoning due to myocar-
dial depressors such as β-blockers and calcium channel blockers, 
instead of glucagon;7,26 and L-carnitine for severe poisoning caused 
by sodium valproate and valproic acid.27 All of these antidotes are 
stocked in the regional reference service.
Although the cost of some antidotes may appear to be rather high 
in the context of Brazil’s healthcare system, acquisition of high-cost 
antidotes could be included in the strategic pharmaceutical assistance 
component of the Brazilian Ministry of Health, which deals with 
neglected situations and market availability. Such inclusions would 
markedly reduce the cost of importation of various antidotes and allow 
the demands of a greater number of states and municipalities to be 
met. In this regard, in 2014, at the time when the soccer World Cup 
was being organized in Brazil, the Campinas Poison Control Center 
received a supply of hydroxocobalamin sufficient for ten treatments, 
and the equivalent of four treatments of pralidoxime. Treatment for 
cyanide poisoning with hydroxocobalamin has been approved by the 
Brazilian Ministry of Health, with publication of an official guideline 
and further incorporation in SUS in 2016.28,29 It is valid to say that 
tragic events, especially the Santa Maria fire in 2013, played an impor-
tant role in the approval of this antidote in particular. The conclusion 
of a previous paper in this field remains up-to-date: “Procrastination, 
fragmentation of responsibilities and improvisation in this area need 
to be tackled. A policy that anticipates great commotion events or 
calamity in public health is a pressing need”.8
Antidote availability in the municipality of Campinas, São Paulo, Brazil | ORIGINAL ARTICLE
Sao Paulo Med J. 2017; 135(1):15-22     21
As shown here, this discussion needs to be expanded to define 
stocks in relation to the immediate needs of emergency rooms 
and the local epidemiology of poisonings. A recent advance in 
this regard has been the implementation of an “antidote policy” 
by the Secretary of Health in the state of Santa Catarina, south-
ern Brazil, based on the strategy adopted in the UK. This policy 
was formulated in partnership with the local Poison Control 
Center to incorporate it into the state emergency care network.30 
This policy and its implementation could provide a basis for cre-
ation of similar systems in other Brazilian states or even a basis 
for a national policy. 
In the present survey, we only considered antidotes that are 
essential for appropriate emergency care of poisoning cases. In low-
resource settings, the need for all acute hospitals to stock all of the 
available recommended antidotes may be unrealistic because of 
economic constraints. In these situations, strategies such as inter-
hospital transfer of antidotes may be effective for treating acute 
poisonings that require expensive, rarely used antidotes, such as 
anti-digoxin antibodies. With this system in operation, it would 
perhaps be irrelevant whether only one or two local hospitals had 
all of the recommended antidotes. Indeed, these approaches have 
frequently been used in Campinas, coordinated by the local Poison 
Control Center, such as the interchange of affordable antidotes like 
acetylcysteine, ethanol 100%, dimercaprol and antivenins.
CONCLUSION
In conclusion, the antidote stocks in the emergency services of 
the municipality of Campinas are incomplete and need to be 
improved. Our situational awareness can be useful as a starting 
point in other contexts. For clinical practice, the present findings 
emphasize the need for an antidote access policy. Further investi-
gations should focus on a national consensus for minimum anti-
dotes and regular stockpile surveys.
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